BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 18, 2005
View Archived Issues
Dendreon Shows Survival Benefit In Phase III Study Of Provenge
A month after reporting a miss in a Phase III trial of its prostate cancer drug Provenge, Dendreon Corp. rebounded with data from the study showing a statistical improvement in patient survival rate. (BioWorld Today)
Read More
FDA Doctor Questions Need For Any Drugs From the COX-2 Class
Read More
'Matchmaker' SNP Study Paves Way For Pharmacogenomics
Read More
BioCryst Raises $23.9M Privately To Fund Lead Clinical Products
Read More
Holiday Notice
Read More
Other News To Note
Read More